Drug Combination May Prove Effective To Prevent Recurrence Of Hepatitis C After Transplantation

November 05, 1998

Hepatitis C is the most common indication for liver transplantation, yet it recurs in almost all patients after transplantation and cannot be successfully treated, even with alpha-interferon. A preliminary study of 20 liver transplant recipients who were treated with a combination of ribavirin and interferon for a year following their transplants suggests this drug regimen can be effective in eradicating the virus and be safely tolerated by patients. Thirteen patients completed the one-year treatment study conducted at the UPMC. Four patients did not respond to therapy as measured by detectable active virus in their blood. But in nine patients evidence of the virus disappeared, at least for the duration of the therapy, Dr. Dodson will report Saturday, Nov. 7. Five patients relapsed within one month of completing the one-year study, but four remained free of the virus three to five months after stopping the drug treatment. Dr. Dodson suggests earlier treatment, before significant liver damage has occurred, may be more effective.

CONTACT: Lisa Rossi 412-647-3555

The scientific meeting will also include a day-long series of debates on "Clinical and Administrative Controversies in Liver and Pancreas Transplantation" scheduled for Saturday, Nov. 7. The UPMC, which has strongly advocated for changes in the organ allocation system, will participate in two of three debates on this subject.
-end-


University of Pittsburgh Medical Center

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.